Mavrilimumab
Mavrilimumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against granulocyte-macrophage colony-stimulating factor receptor subunit alpha.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 5 | 1 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 4 | — | — | — | 5 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 3 | — | — | — | 3 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | 2 | — | — | — | 2 | |
| Sars-cov-2 | D000086402 | — | 2 | — | — | — | 2 | ||
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | — | — | — | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | — | 1 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MAVRILIMUMAB |
| INN | mavrilimumab |
| Description | Mavrilimumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1085337-57-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743039 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12534 |
| UNII ID | 1158JD1P9A (ChemIDplus, GSRS) |
Target
Agency Approved
CSF2RA
CSF2RA
Organism
Homo sapiens
Gene name
CSF2RA
Gene synonyms
CSF2R, CSF2RY
NCBI Gene ID
Protein name
granulocyte-macrophage colony-stimulating factor receptor subunit alpha
Protein synonyms
alpha-GM-CSF receptor, CD116, CD116 antigen, CDw116, colony stimulating factor 2 receptor alpha subunit, colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage), GM-CSF receptor alpha subunit, granulocyte-macrophage colony-stimulating factor receptor alpha chain
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 502 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more